Biomedical papers, 2017 (vol. 161), issue 3

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017, 161(3):296-302 | 10.5507/bp.2017.015

Higher levels of matrix metalloproteinase-3 in patients with RA reflect disease activity and structural damage

Martina Skacelovaa, Zuzana Hermanovab, Pavel Horaka, Ahmed Kazia, Katerina Langovac
a Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
b Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
c Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic

Aims: To evaluate the serum levels of matrix metalloproteinase-3 (MMP-3) as a potential marker of disease activity and joint damage in 92 patients with rheumatoid arthritis (RA), compared to 24 osteoarthritis (OA) patients and 26 healthy controls.

Methods: The concentrations of MMP-3 were measured by ELISA using the commercial kit AESKULISA DF MMP-3 (AESKU.Diagnostics, Germany) and compared with other laboratory parameters routinely used to assess the disease status, clinical score (DAS28) and radiographic stage in the group of RA patients.

Results: The mean serum concentrations of MMP-3 were 199.1 ± 160 ng/mL in RA patients, 113.9 ± 96.9 ng/mL in OA patients and 48.3 ± 19.2 in healthy controls. The differences were highly significant: RA patients and healthy controls (P<0.0001), RA and OA patients (P=0.008) as well as between OA patients and controls (P=0.009). MMP-3 concentrations were further compared with other laboratory parameters and clinical and structural damage data. There were correlations between MMP-3 and CRP (r=0.304, P<0.01), DAS28 (r=0.301, P<0.05), levels of anti-cyclic citrullinated peptide antibodies (r=0.241, P<0.05), erythrocyte sedimentation rate (r=0.200, P=0.059) and radiographic disease stage (r=0.197, P=0.063).

Conclusion: These results demonstrated that measurement of MMP-3 could become a marker of disease activity in RA patients.

Keywords: rheumatoid arthritis, disease activity, matrix metalloproteinase-3

Received: December 12, 2016; Accepted: March 22, 2017; Prepublished online: April 26, 2017; Published: September 26, 2017


References

  1. Pavelka K, Vencovský J. Recommendations of the Czech Society for Rheumatology for the treatment of rheumatoid arthritis. Čes Revmatol 2010;18(4):182-91.
  2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19. Go to original source... Go to PubMed...
  3. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nature Reviews Immunology 2007;7:429-42. Go to original source... Go to PubMed...
  4. Jones GC, Riley GP, Buttle DJ. The role of proteases in pathologies of the synovial joint. International Journal of Biochemistry and Cell Biology 2008;40(6-7):1199-218. Go to original source... Go to PubMed...
  5. Galliera E, Banfi G, Corsi MM. Human bone disorders: pathological role and diagnostic potential of matrix metalloproteinases. International Journal of Biochemistry and Cell Biology 2010;42(10):1590-3. Go to original source... Go to PubMed...
  6. Manicone AM, McGuire JK. Matrix metalloproteinases as modulators of inflammation. Seminars in Cell and Developmental Biology 2008;19(1):34-41.  Go to original source... Go to PubMed...
  7. Hueber AJ, Asquith DL, McInnes IB, Miller AM. Embracing novel cytokines in RA - complexity grows as does opportunity! Best Practice and Research 2010;24(4):479-87.  Go to original source... Go to PubMed...
  8. Connolly M, Mullan RH, McCormick J, Matthews C, Sullivan O, Kennedy A, FitzGerald O, Poole AR, Bresnihan B, Veale DJ, Fearon U. Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis and Rheumatism 2012;64(4):1035-45.  Go to original source... Go to PubMed...
  9. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;(141):52-67. Go to original source...
  10. Kessenbrock K, Wang CY, Werb Z. Matrix metalloproteinases in stem cell regulation and cancer. Matrix Biol;2015(44-46):184-90. Go to original source...
  11. Beidler SK, Douillet CD, Berndt DF, Keagy BA, Rich PB, Marston WA. Multiplexed analysis of matrix metalloproteinases in leg ulcer tissue of patients with chronic venous insufficiency before and after compression therapy. Wound Repair and Regeneration 2008;16:642-8. Go to original source... Go to PubMed...
  12. Denarie D, Constant E, Thomas T, Marotte H. Could biomarkers of bone, cartilage or synovium turnover be used for relapse prediction in rheumatoid arthritis patients? Mediators Inflamm 2014;2014:537324. Go to original source... Go to PubMed...
  13. Ma JD, Zhou JJ, Zheng DH, Chen LF, Mo YQ, Wei XN, Yang LJ, Dai L. Serum matrix metalloproteinase-3 as a noninvasive biomarker of histological synovitis for diagnosis of rheumatoid arthritis. Mediators Inflamm 2014;2014:179284. Go to PubMed...
  14. Ma JD, Ou-Yang X, Zheng DH, Mo YQ, Zou CJ, Zhu LJ. Combined detection of serum matrix metalloproteinase-3 and C-reactive protein in disease activity measurement in female patients with rheumatoid arthritis. Chin J Clinicians (Electronic Edition) 2013;8:3301-5.
  15. Aletaha D, Neogi T, Silman AJ,  Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-88. Go to original source... Go to PubMed...
  16. Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, Brown C, Cooke TD, Daniel W, Gray R. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 1990;33:1601. Go to original source... Go to PubMed...
  17. Instruction for Immunoscan CCPlus, document E-23-0182-12, November 2015.
  18. Instruction for N Latex RF Kit, Edition July 2011.
  19. Bedell SE, Bush BT. Erythrocyte sedimentation rate. From folklore to facts. Am J Med 1985;78:1001. Go to original source... Go to PubMed...
  20. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL.Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44. Go to original source... Go to PubMed...
  21. Steinbrocker O, Traeger GH, Battermann RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62. Go to original source...
  22. Boini S, Guillemin F: Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. Ann Rheum Dis 2001,60:817-27. Go to PubMed...
  23. Urata Y, Uesato R, Tanaka D, Nakamura Y, Motomura S. Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study. Ann Rheum Dis 2012;71:534-40. Go to original source... Go to PubMed...
  24. Shiozawa K, Yamane T, Murata M, Yoshihara R, Tsumiyama K, Imura,S, Shiozawa S. MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy. Arthritis Research & Therapy 2016;18:55. doi:10.1186/s13075-016-0948-7 Go to original source...
  25. Ma MJ, Liu HC, Qu XQ, Wang JL. Matrix metalloproteinase-3 gene polymorphism and its mRNA expression in rheumatoid arthritis. Genet Mol Res 2015;14(4):15652-9. doi: 10.4238/2015 Go to original source... Go to PubMed...
  26. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci 2006;11:529-43. Go to original source... Go to PubMed...
  27. Mamehara A, Sugimoto T, Sugiyama D, Morinobu S, Tsuji G, Kawano S, Morinobu A, Kumagai S. Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs. Kobe J Med Sci 2010;56(3):98-7. Go to PubMed...
  28. Ally MMTM, Hodkinson B, Meyer PWA, Musenge E, Tikly M, Anderson R. Serum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis. Mediators of Inflammation 2013;2013:6.
  29. Yamanaka H, Matsuda Y, Tanaka M,  Sendo W, Nakajima H, Taniguchi A, Kamatani N. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000;43:852-8. Go to original source... Go to PubMed...
  30. Keyszer G, Lambiri I, Nagel R, Keysser C, Keysser M, Gromnica-Ihle E, Franz J, Burmester GR, Jung K. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. The Journal of Rheumatology 1999;26(2):251-8. Go to PubMed...
  31. Ribbens C, Andre B, Jaspar JM, Kaye O, Kaiser MJ, De Groote D, Malaise MG. Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. The Journal of Rheumatology 2000;27(4):888-3. Go to PubMed...
  32. Shiozawa K, Yamane T, Murata M, Yoshihara R, Tsumiyama K, Imura S, Shiozawa S. MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy. Arthritis Res Ther 2016;18:55. Go to original source... Go to PubMed...
  33. Ma J-D, Wei X-N, Zheng D-H, Mo Y-Q, Chen L-F, Zhang X, Li J-H, Dai L. Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predicts one-year radiographic progression in rheumatoid arthritis: a prospective cohort study. Arthritis Res Ther 2014;17: 289. doi: 10.1186/s13075-015-0803-2 Go to original source...
  34. Nawata M, Saito K, Fukuyo S, Hirata S, Tanaka Y. Clinically relevant radiographic progression in joint destruction in RA patients with abnormal MMP-3 or high levels of CRP despite 1-year treatment with infliximab. Mod Rheumatol 2016 Apr 26:1-6. [Epub ahead of print] doi:10.3109/14397595.2016.1158386 Go to original source... Go to PubMed...
  35. Abd El-Aziz TA, Mohamed RH. Matrix metalloproteinase 3 gene polymorphism and its level predict morbidity after acute myocardial infarction. Am J Clin Pathol 2016;145(1):134-9. Go to original source... Go to PubMed...
  36. Tepliakov AT, Berezikova EN, Shilov SN, Grakova EV, Torim IuIu, Efremov AV, Safronov ID, Pustovetova MG, Karpov RS. Assessment of the role of matrix metalloproteinase-3 gene polymorphism in the development of chronic heart failure. Ter Arkh 2015;87(4):8-12. Go to original source... Go to PubMed...
  37. Collazos J, Asensi V, Martin G, Montes AH, Suárez-Zarracina T, Valle-Garay E. The effect of gender and genetic polymorphisms on matrix metalloprotease (MMP) and tissue inhibitor (TIMP) plasma levels in different infectious and non-infectious conditions. Clin Exp Immunol 2015;182(2):213-9. Go to original source... Go to PubMed...
  38. Houseman M, Potter C, Marshall N, Lakey R, Cawston T, Griffiths I, Young-Min S, Isaacs JD. Baseline serum MMP-3 levels in patients with rheumatoid arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. Arthritis Res Ther 2012;14(1):R30. doi: 10.1186/ar3734 Go to original source... Go to PubMed...